39th Annual Meeting of the European Bone and Joint Infection Society

• 39th Annual Meeting of the European Bone and Joint Infection Society
• du 07/10/2021 au 09/10/2021
• Ljubljana, Slovenia

Posters

CEFTAROLINE AND CEFTOBIPROLE: REAL LIFE OFF LABEL USE IN PATIENTS WITH BJI OF THESE TWO BETALACTAMS ACTIVE AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCI

• Triffault-Fillit C
• Valour F
• Laurent F
• Goutelle S
• Chidiac C
• Ferry T
• on behalf of Lyon BJI Study Group

IMPLEMENTATION OF A PHAGE THERAPY CENTER IN FRANCE DEDICATED TO COMPLEX BONE AND JOINT INFECTION: 4-YEAR EXPERIENCE OF MULTIDISCIPLINARITY AND MULTISTEP INTERACTIONS

• Ferry T
• Kolenda C
• Briot T
• Lustig S
• Batailler C
• Leboucher G
• Laurent F
• on behalf of Lyon BJI Study Group

Communications orales

Bone and Joint Infections : synergistic antibiofilm effect of exebacase and antibiotics against Staphylococcus epidermidis strains

• Kolenda C

Development of phage therapy to treat staphylococci bone and joint infections in France: isolation and characterization of seventeen novel anti Staphylococcus bacteriophages

• Kolenda C

In patients with BJI, 6 and 12 weeks of antimicrobial therapy seems to have a similar impact on the gut microbiota and no particular antibiotic seems to impact its recovery

• Ferry T

Conservative management of chronic infections: Experience with subcutaneous antimicrobial suppressive treatment and bacteriophages

• Ferry T

Plasma Cell Infiltration on Histopathological Samples of Chronic Bone and Joint Infections due to Cutibacterium acnes: A series of 21 cases

• Trécourt A

Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study

• Pham TT